Fig. 4

Treatment effects of ipragliflozin and sitagliptin on serum apolipoproteins. Changes from baseline in serum apolipoprotein (Apo) AI (mg/dL) (A), AII (mg/dL) (B), B (mg/dL) (C), B48 (µg/dL) (D), CII (mg/dL) (E), CIII (mg/dL) (F), and E (mg/dL) (G) in the ipragliflozin and sitagliptin groups are shown as closed circles with blue lines and closed squares with red lines, respectively. Data are expressed as mean ± 95% confidence interval of the mean. *, P < 0.05; **, P < 0.01, ***, P < 0.001 vs. baseline in each group; ††, P < 0.01 for difference at the follow up visit; ‡‡, P < 0.01 for difference during the overall study period, vs. the sitagliptin group in the mixed-effects model analysis